Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Kinjal Thakor, Shelly Naud, Diantha Howard, Rup Tandan & Waqar Waheed. (2021) Effect of riluzole on weight in short-term and long-term survivors of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 22:5-6, pages 360-367.
Read now
Read now
Marion C. Hogg, Luise Halang, Ina Woods, Karen S. Coughlan & Jochen H. M. PREHN. (2018) Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:5-6, pages 438-445.
Read now
Read now
R. Navanietha Krishnaraj, S. S. Sreeja Kumari & Sudit Sekhar Mukhopadhyay. (2016) Antagonistic molecular interactions of photosynthetic pigments with molecular disease targets: a new approach to treat AD and ALS. Journal of Receptors and Signal Transduction 36:1, pages 67-71.
Read now
Read now
Masaaki Konishi, Nicole Ebner, Stephan von Haehling, Stefan D Anker & Jochen Springer. (2015) Developing models for cachexia and their implications in drug discovery. Expert Opinion on Drug Discovery 10:7, pages 743-752.
Read now
Read now
Lucio Tremolizzo, Paolo Messina, Elisa Conti, Gessica Sala, Matteo Cecchi, Luisa Airoldi, Roberta Pastorelli, Elisabetta Pupillo, Monica Bandettini Di Poggio, Massimiliano Filosto, Christian Lunetta, Cristina Agliardi, Franca Guerini, Jessica Mandrioli, Andrea Calvo, Ettore Beghi, Carlo Ferrarese, M.S. Cotelli, M. Corbo, E. Maestri, E. Georgoulopoulou, L. Marzorati, E. Susani, A. Arosio, A. Chiò, G. Fuda & F. Pisa. (2014) Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onset. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15:1-2, pages 98-105.
Read now
Read now
Michael P Bova & Gene G Kinney. (2013) Emerging drug targets in amyotrophic lateral sclerosis. Expert Opinion on Orphan Drugs 1:1, pages 5-20.
Read now
Read now
Stefano Zoccolella, Andrea Santamato & Paolo Lamberti. (2009) Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatric Disease and Treatment 5, pages 577-595.
Read now
Read now
Articles from other publishers (65)
Eleanor Roberts. (2023) A Review of Oral Fixed-Dose Sodium Phenylbutyrate and Ursodoxicoltaurine in People with Amyotrophic Lateral Sclerosis. EMJ Neurology, pages 2-12.
Crossref
Crossref
Shivangi Patel, Arnika Pangarkar, Sakshi Mahajan & Anuradha Majumdar. (2023) Therapeutic potential of endoplasmic reticulum stress inhibitors in the treatment of diabetic peripheral neuropathy. Metabolic Brain Disease 38:6, pages 1841-1856.
Crossref
Crossref
Laura Tzeplaeff, Sibylle Wilfling, Maria Viktoria Requardt & Meret Herdick. (2023) Current State and Future Directions in the Therapy of ALS. Cells 12:11, pages 1523.
Crossref
Crossref
Sarah Hassan, Mario Eid, Ahmad Hassan & Samer El Hayek. 2023. Trace Elements in Brain Health and Diseases. Trace Elements in Brain Health and Diseases
155
168
.
Edoardo Parrella, Vanessa Porrini, Ilaria Scambi, Michele M. Gennari, Cristina Gussago, Oluwamolakun Bankole, Marina Benarese, Raffaella Mariotti & Marina Pizzi. (2022) Synergistic association of resveratrol and histone deacetylase inhibitors as treatment in amyotrophic lateral sclerosis. Frontiers in Pharmacology 13.
Crossref
Crossref
Matthew E. R. Butchbach & Rod C. Scott. (2022) Biological networks and complexity in early-onset motor neuron diseases. Frontiers in Neurology 13.
Crossref
Crossref
Johannes Dorst & Angela Genge. (2022) Clinical studies in amyotrophic lateral sclerosis. Current Opinion in Neurology 35:5, pages 686-692.
Crossref
Crossref
Leenor Alfahel, Shirel Argueti-Ostrovsky, Shir Barel, Mahmood Ali Saleh, Joy Kahn, Salome Azoulay-Ginsburg, Ayelet Rothstein, Simon Ebbinghaus, Arie Gruzman & Adrian Israelson. (2022) 4-Phenylbutyric Acid (4-PBA) Derivatives Prevent SOD1 Amyloid Aggregation In Vitro with No Effect on Disease Progression in SOD1-ALS Mice. International Journal of Molecular Sciences 23:16, pages 9403.
Crossref
Crossref
Elías Marlin, Cristina Viu-Idocin, Montserrat Arrasate & Tomás Aragón. (2022) The Role and Therapeutic Potential of the Integrated Stress Response in Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences 23:14, pages 7823.
Crossref
Crossref
Kareem Khalaf, Paolo Tornese, Antoniangela Cocco & Alberto Albanese. (2022) Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Translational Neurodegeneration 11:1.
Crossref
Crossref
Swati Dhasmana, Anupam Dhasmana, Acharan S. Narula, Meena Jaggi, Murali M. Yallapu & Subhash C. Chauhan. (2022) The panoramic view of amyotrophic lateral sclerosis: A fatal intricate neurological disorder. Life Sciences 288, pages 120156.
Crossref
Crossref
Michail S. Kukharsky, Veronika I. Skvortsova, Sergey O. Bachurin & Vladimir L. Buchman. (2020) In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches. Medicinal Research Reviews 41:5, pages 2804-2822.
Crossref
Crossref
Yvonne E. Klingl, Donya Pakravan & Ludo Van Den Bosch. (2020) Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis. British Journal of Pharmacology 178:6, pages 1353-1372.
Crossref
Crossref
Nicoletta Nuzziello & Maria Liguori. 2021. Medical Epigenetics. Medical Epigenetics
559
581
.
Sabrina PaganoniEric A. MacklinSuzanne HendrixJames D. BerryMichael A. ElliottSamuel MaiserChafic KaramJames B. CaressMargaret A. OwegiAdam QuickJames WymerStephen A. GoutmanDaragh HeitzmanTerry Heiman-PattersonCarlayne E. JacksonColin QuinnJeffrey D. RothsteinEdward J. KasarskisJonathan KatzLiberty JenkinsShafeeq LadhaTimothy M. MillerStephen N. ScelsaTuan H. VuChristina N. FournierJonathan D. GlassKristin M. JohnsonAndrea SwensonNamita A. GoyalGary L. PatteePatricia L. AndresSuma BabuMarianne ChaseDerek DagostinoSamuel P. DicksonNoel EllisonMeghan HallKent HendrixGale KittleMichelle McGovernJoseph OstrowLindsay PothierRebecca RandallJeremy M. ShefnerAlexander V. ShermanEric TustisonPrasha VigneswaranJason WalkerHong YuJames ChanJanet WittesJoshua CohenJustin KleeKent LeslieRudolph E. TanziWalter GilbertPatrick D. YeramianDavid SchoenfeldMerit E. Cudkowicz. (2020) Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine 383:10, pages 919-930.
Crossref
Crossref
Michele Longoni Calió, Elisandra Henriques, Amanda Siena, Clélia Rejane Antonio Bertoncini, Joana Gil-Mohapel & Tatiana Rosado Rosenstock. (2020) Mitochondrial Dysfunction, Neurogenesis, and Epigenetics: Putative Implications for Amyotrophic Lateral Sclerosis Neurodegeneration and Treatment. Frontiers in Neuroscience 14.
Crossref
Crossref
Surabhi Shukla & Babu L. Tekwani. (2020) Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation. Frontiers in Pharmacology 11.
Crossref
Crossref
Yasuhiro Kosuge, Erina Kaneko, Hiroshi Nango, Hiroko Miyagishi, Kumiko Ishige & Yoshihisa Ito. (2020)
Bidens pilosa
Extract Administered after Symptom Onset Attenuates Glial Activation, Improves Motor Performance, and Prolongs Survival in a Mouse Model of Amyotrophic Lateral Sclerosis
. Oxidative Medicine and Cellular Longevity 2020, pages 1-11.
Crossref
Crossref
Elisabeth Rossaert, Eveliina Pollari, Tom Jaspers, Lawrence Van Helleputte, Matthew Jarpe, Philip Van Damme, Katrien De Bock, Matthieu Moisse & Ludo Van Den Bosch. (2019) Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model. Acta Neuropathologica Communications 7:1.
Crossref
Crossref
Joana G Fernandes, Nuno H Franco, Andrew J Grierson, Jan Hultgren, Andrew J W Furley & I Anna S Olsson. (2019) Methodological standards, quality of reporting and regulatory compliance in animal research on amyotrophic lateral sclerosis: a systematic review. BMJ Open Science 3:1, pages e000016.
Crossref
Crossref
Samantha N. Cobos, Seth A. Bennett & Mariana P. Torrente. (2019) The impact of histone post-translational modifications in neurodegenerative diseases. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1865:8, pages 1982-1991.
Crossref
Crossref
Seth A. Bennett, Royena Tanaz, Samantha N. Cobos & Mariana P. Torrente. (2019) Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease. Translational Research 204, pages 19-30.
Crossref
Crossref
Shabir Ahmad GanaiShabir Ahmad Ganai. 2019. Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders. Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders
77
89
.
Malgorzata Ziemka-Nalecz, Joanna Jaworska, Joanna Sypecka & Teresa Zalewska. (2018) Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?. Journal of Neuropathology & Experimental Neurology 77:10, pages 855-870.
Crossref
Crossref
Lorenzo Schiaffino, Roberta Bonafede, Ilaria Scambi, Edoardo Parrella, Marina Pizzi & Raffaella Mariotti. (2018) Acetylation state of RelA modulated by epigenetic drugs prolongs survival and induces a neuroprotective effect on ALS murine model. Scientific Reports 8:1.
Crossref
Crossref
Tetsuya Toba, Ryosuke Suzuki, Junko Futamura-Takahashi, Yoshito Kawamoto, Shigeki Tamura, Mariko Kuroda, Yoshiari Shimmyo, Michinori Kadokura, Kazumichi Goto, Teruyoshi Inoue, Tsuyoshi Muto & Hirokazu Annoura. (2018) Synthesis and evaluation of N -(4-benzylphenyl)piperazines as VGF inducers. Bioorganic & Medicinal Chemistry Letters 28:14, pages 2528-2532.
Crossref
Crossref
Alexandre Henriques, Vincent Croixmarie, Alexandra Bouscary, Althéa Mosbach, Céline Keime, Claire Boursier-Neyret, Bernard Walter, Michael Spedding & Jean-Philippe Loeffler. (2018) Sphingolipid Metabolism Is Dysregulated at Transcriptomic and Metabolic Levels in the Spinal Cord of an Animal Model of Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience 10.
Crossref
Crossref
Hamid Hamzeiy, Doruk Savaş, Ceren Tunca, Nesli Ece Şen, Aslı Gündoğdu Eken, Irmak Şahbaz, Daniela Calini, Cinzia Tiloca, Nicola Ticozzi, Antonia Ratti, Vincenzo Silani & A. Nazlı Başak. (2018) Elevated Global DNA Methylation Is Not Exclusive to Amyotrophic Lateral Sclerosis and Is Also Observed in Spinocerebellar Ataxia Types 1 and 2. Neurodegenerative Diseases 18:1, pages 38-48.
Crossref
Crossref
Bhavneet Kaur, Ajay Bhat, Rahul Chakraborty, Khushboo Adlakha, Shantanu Sengupta, SoumyaSinha Roy & Kausik Chakraborty. (2018) Proteomic profile of 4-PBA treated human neuronal cells during ER stress. Molecular Omics 14:1, pages 53-63.
Crossref
Crossref
Andréia Cristina Karklin Fontana. 2018. Biochemical Approaches for Glutamatergic Neurotransmission. Biochemical Approaches for Glutamatergic Neurotransmission
169
225
.
Shivangi Patel, Dilip Sharma, Kiran Kalia & Vinod Tiwari. (2017) Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches. Neuroscience & Biobehavioral Reviews 83, pages 589-603.
Crossref
Crossref
Min Jee Kwon, Jeong-Hoon Kim, TaeSoo Kim & Sung Bae Lee. (2017) Pharmacological intervention of early neuropathy in neurodegenerative diseases. Pharmacological Research 119, pages 169-177.
Crossref
Crossref
Alba Jimenez-Pacheco, Jaime M. Franco, Soledad Lopez, Juan Miguel Gomez-Zumaquero, Maria Magdalena Leal-Lasarte, Diana E. Caballero-Hernandez, Marta Cejudo-Guillén & David Pozo. 2017. Neuroepigenomics in Aging and Disease. Neuroepigenomics in Aging and Disease
255
275
.
William DeCoteau, Karin L. Heckman, Ana Y. Estevez, Kenneth J. Reed, Wendi Costanzo, David Sandford, Paige Studlack, Jennifer Clauss, Elizabeth Nichols, Jennifer Lipps, Matthew Parker, Bonnie Hays-Erlichman, J.C. Leiter & Joseph S. Erlichman. (2016) Cerium oxide nanoparticles with antioxidant properties ameliorate strength and prolong life in mouse model of amyotrophic lateral sclerosis. Nanomedicine: Nanotechnology, Biology and Medicine 12:8, pages 2311-2320.
Crossref
Crossref
Shabir Ahmad Ganai, Shahid Banday, Zeenat Farooq & Mohammad Altaf. (2016) Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders. Pharmacology & Therapeutics 166, pages 106-122.
Crossref
Crossref
Kuo-Wei Hsueh, Tzyy-Wen Chiou, Shu-Fen Chiang, Toru Yamashita, Koji Abe, Cesar V. Borlongan, Paul R. Sanberg, Angela (Yu Hsuan) Huang, Shinn-Zong Lin & Horng-Jyh Harn. (2016) Autophagic down-regulation in motor neurons remarkably prolongs the survival of ALS mice. Neuropharmacology 108, pages 152-160.
Crossref
Crossref
Matthew E.R. Butchbach, Casey J. Lumpkin, Ashlee W. Harris, Luciano Saieva, Jonathan D. Edwards, Eileen Workman, Louise R. Simard, Livio Pellizzoni & Arthur H.M. Burghes. (2016) Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy. Experimental Neurology 279, pages 13-26.
Crossref
Crossref
Anastasios Fotinos, Yongjin Zhu, Lilly L. J. Mao, Nazem Atassi, Edward W. Zhou, Sarfraz Ahmad, Yingjun Guan, James D. Berry, Merit E. Cudkowicz & Xin Wang. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
869
903
.
Ankit Tripathi, Renu Sharma, Noopur Kejriwal, Rashmi K. Ambasta & Pravir Kumar. 2016. Epigenetic Advancements in Cancer. Epigenetic Advancements in Cancer
177
205
.
Saravanan S. Karuppagounder, Amit Kumar, Diana S. Shao, Marietta Zille, Megan W. Bourassa, Joseph T. Caulfield, Ishraq Alim & Rajiv R. Ratan. (2015) Metabolism and epigenetics in the nervous system: Creating cellular fitness and resistance to neuronal death in neurological conditions via modulation of oxygen-, iron-, and 2-oxoglutarate-dependent dioxygenases. Brain Research 1628, pages 273-287.
Crossref
Crossref
Andréia C. K. Fontana. (2015) Current approaches to enhance glutamate transporter function and expression. Journal of Neurochemistry 134:6, pages 982-1007.
Crossref
Crossref
Ana C. Sirianni, Jiying Jiang, Jiang Zeng, Lilly L. Mao, Shuanhu Zhou, Peter Sugarbaker, Xinmu Zhang, Wei Li, Robert M. Friedlander & Xin Wang. (2015)
N-acetyl-
l
-tryptophan, but not N-acetyl-
d
-tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis
. Journal of Neurochemistry 134:5, pages 956-968.
Crossref
Crossref
Ximena Paez-Colasante, Claudia Figueroa-Romero, Stacey A. Sakowski, Stephen A. Goutman & Eva L. Feldman. (2015) Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. Nature Reviews Neurology 11:5, pages 266-279.
Crossref
Crossref
Yongjin Zhu, Anastasios Fotinos, Lilly L.J. Mao, Nazem Atassi, Edward W. Zhou, Sarfraz Ahmad, Yingjun Guan, James D. Berry, Merit E. Cudkowicz & Xin Wang. (2015) Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discovery Today 20:1, pages 65-75.
Crossref
Crossref
Michael R. Jablonski, Shashirekha S. Markandaiah, Dena Jacob, Ni J. Meng, Ke Li, Victoria Gennaro, Angelo C. Lepore, Davide Trotti & Piera Pasinelli. (2014)
Inhibiting drug efflux transporters improves efficacy of
ALS
therapeutics
. Annals of Clinical and Translational Neurology 1:12, pages 996-1005.
Crossref
Crossref
Jin A. Cho, Xuan Zhang, Gregory M. Miller, Wayne I. Lencer & Flavia C. Nery. (2014) 4-Phenylbutyrate Attenuates the ER Stress Response and Cyclic AMP Accumulation in DYT1 Dystonia Cell Models. PLoS ONE 9:11, pages e110086.
Crossref
Crossref
Fabio Coppedè. (2014) The potential of epigenetic therapies in neurodegenerative diseases. Frontiers in Genetics 5.
Crossref
Crossref
C Valle, I Salvatori, V Gerbino, S Rossi, L Palamiuc, F René & M T Carrì. (2014) Tissue-specific deregulation of selected HDACs characterizes ALS progression in mouse models: pharmacological characterization of SIRT1 and SIRT2 pathways. Cell Death & Disease 5:6, pages e1296-e1296.
Crossref
Crossref
Barış Genç & P. Hande Özdinler. (2014) Moving forward in clinical trials for ALS: motor neurons lead the way please. Drug Discovery Today 19:4, pages 441-449.
Crossref
Crossref
Seisuke Mimori, Hiroyasu Ohtaka, Yukari Koshikawa, Koichi Kawada, Masayuki Kaneko, Yasunobu Okuma, Yasuyuki Nomura, Yasuoki Murakami & Hiroshi Hamana. (2013) 4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor. Bioorganic & Medicinal Chemistry Letters 23:21, pages 6015-6018.
Crossref
Crossref
Anne Schneider, Snehajyoti Chatterjee, Olivier Bousiges, B. Ruthrotha Selvi, Amrutha Swaminathan, Raphaelle Cassel, Frédéric Blanc, Tapas K. Kundu & Anne-Laurence Boutillier. (2013) Acetyltransferases (HATs) as Targets for Neurological Therapeutics. Neurotherapeutics 10:4, pages 568-588.
Crossref
Crossref
Frederick A. Schroeder, Michael C. Lewis, Daniel M. Fass, Florence F. Wagner, Yan-Ling Zhang, Krista M. Hennig, Jennifer Gale, Wen-Ning Zhao, Surya Reis, Douglas D. Barker, Erin Berry-Scott, Sung Won Kim, Elizabeth L. Clore, Jacob M. Hooker, Edward B. Holson, Stephen J. Haggarty & Tracey L. Petryshen. (2013) A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests. PLoS ONE 8:8, pages e71323.
Crossref
Crossref
Elsa FritzPamela IzaurietaAlexandra WeissFranco R. Mir, Patricio Rojas, David GonzalezFabiola RojasRobert H. BrownJr.Jr., Rodolfo Madrid & Brigitte van Zundert. (2013) Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability. Journal of Neurophysiology 109:11, pages 2803-2814.
Crossref
Crossref
Stefka Mincheva-Tasheva & Rosa M. Soler. (2012) NF-κB Signaling Pathways. The Neuroscientist 19:2, pages 175-194.
Crossref
Crossref
Tian Chen, Radhia Benmohamed, Jinho Kim, Karen Smith, Daniel Amante, Richard I. Morimoto, Donald R. Kirsch, Robert J. Ferrante & Richard B. Silverman. (2011) ADME-Guided Design and Synthesis of Aryloxanyl Pyrazolone Derivatives To Block Mutant Superoxide Dismutase 1 (SOD1) Cytotoxicity and Protein Aggregation: Potential Application for the Treatment of Amyotrophic Lateral Sclerosis. Journal of Medicinal Chemistry 55:1, pages 515-527.
Crossref
Crossref
J. E. SchusterR. FuT. SiddiqueC. J. Heckman. (2012) Effect of prolonged riluzole exposure on cultured motoneurons in a mouse model of ALS. Journal of Neurophysiology 107:1, pages 484-492.
Crossref
Crossref
Jonathan D. Glass. (2012) New drugs for ALS: How do we get there?. Experimental Neurology 233:1, pages 112-117.
Crossref
Crossref
Sabrina Schäfer & Emmanuel Hermans. (2011) Reassessment of motor-behavioural test analyses enables the detection of early disease-onset in a transgenic mouse model of amyotrophic lateral sclerosis. Behavioural Brain Research 225:1, pages 7-14.
Crossref
Crossref
Tommaso Iannitti & Beniamino Palmieri. (2012) Clinical and Experimental Applications of Sodium Phenylbutyrate. Drugs in R&D 11:3, pages 227-249.
Crossref
Crossref
Tommaso Iannitti & Beniamino Palmieri. (2012) Clinical and Experimental Applications of Sodium Phenylbutyrate. Drugs in R & D 11:3, pages 227-249.
Crossref
Crossref
Jesse A. Solomon, Mark A. Tarnopolsky & Mazen J. Hamadeh. (2011) One Universal Common Endpoint in Mouse Models of Amyotrophic Lateral Sclerosis. PLoS ONE 6:6, pages e20582.
Crossref
Crossref
Mark C. Bellingham. (2011) A Review of the Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating Amyotrophic Lateral Sclerosis: What have we Learned in the Last Decade?. CNS Neuroscience & Therapeutics 17:1, pages 4-31.
Crossref
Crossref
Yan Wang & Zheng-hong Qin. (2010) Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis 15:11, pages 1382-1402.
Crossref
Crossref
B. Ruthrotha Selvi, Jean-Christophe Cassel, Tapas K. Kundu & Anne-Laurence Boutillier. (2010) Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1799:10-12, pages 840-853.
Crossref
Crossref
De-Maw Chuang, Yan Leng, Zoya Marinova, Hyeon-Ju Kim & Chi-Tso Chiu. (2009) Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends in Neurosciences 32:11, pages 591-601.
Crossref
Crossref